20.500.12556/RUL-158178 Prevalence and treatment outcomes of childhood acute lymphoblastic leukemia in Kosovo Advances in research, including novel biomarker identification and patient stratification, have significantly improved the therapy for childhood acute lymphoblastic leukemia (ALL), though access to improved healthcare services varies across geographical regions. In an effort to evaluate the advances in therapeutic approaches, we performed a retrospective analysis of childhood ALL in Kosovo. Our retrospective analysis included 225 cases diagnosed between 2008 and 2023, representing 52% of 429 diagnosed childhood cancers. The average annual incidence was 14, with a median age diagnosis of seven years, and a male predominance (59.54%). Patients were categorized into risk groups, with the majority (43%) in the standard-risk category. We identified five different treatment protocols for this study period. Over 61% of patients achieved remission after the first chemotherapy cycle and we observed a 20% mortality rate. Survival analysis showed that 55% and 40% of patients achieved 2-year and 5-year event-free survival (EFS), respectively, with significant differences across risk groups. Treatment advancements significantly correlated with improved survival rates, achieving a 5-year overall survival (OS) of 88% in the currently used standardized AIEOP-BFM-2009 protocol. Our study emphasizes the need for continued research and customized care strategies to enhance clinical outcomes. acute lymphoblastic leukemia treatment overall survival event-free survival pediatric akutna limfoblastna levkemija zdravljenje pediatrija splošno preživetje preživetje brez dogodkov true false true Angleški jezik Slovenski jezik Članek v reviji 2024-05-28 12:56:47 2024-05-28 12:56:52 2024-06-24 03:44:24 0000-00-00 00:00:00 2024 0 0 13 str. no. 11, art. 1988 Vol. 16 2024 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616.155.392+616-053.2 2072-6694 10.3390/cancers16111988 196879107 cancers-16-01988.pdf cancers-16-01988.pdf 1 0887C0C685B4C1C0C2CCF9A198DC75E6 04447f02594eafa4e7da997e886f1fbd814d6e6bf54fa71e277f9f644e303b39 de5ec4db-1ce1-11ef-a9a3-0050569b8976 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=185672 https://www.mdpi.com/2072-6694/16/11/1988 1 ff072014-1ce0-11ef-a9a3-0050569b8976 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=185671 Fakulteta za farmacijo 0 0 0